POM-V Prescription Required Companion Animal

Lodisure 1 mg Tablets for Cats

Active ingredient: Amlodipine

Form

Tablet

Species

Cats

Manufacturer

Dechra Regulatory B.V.

VMD MA No.

50406/4010

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Amlodipine

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Lodisure 1 mg Tablets for Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

The tablets can be administered directly to the animal or administered with a small
quantity of food.
The recommended standard starting dose is 0.125-0.25 mg amlodipine per kg
bodyweight per day.
Bodyweight range (kg)Number of tablets a
day
2 to < 4 ½Standard posology:≥ 4 to 81
To ensure a correct dosage, body weight should be determined as accurately as
possible.
For cats weighing between 2 kg and 2.5 kg, please refer to section 3.5.
After two weeks of treatment, the clinical response should be re-evaluated. In case of
insufficient clinical response - decrease in SBP less than 15% and SBP still > 150
mm Hg - dose may be increased by 0.5 mg (½ tablet) per day,up to a maximum
dose of 0.5 mg/kg BW daily. See also section 3.5.
Response to dose adjustments should be re-evaluated after another two weeks.
In the event of clinically relevant adverse events decreasing the dose or termination
of treatment should be considered.

Do not use in animals with severe hepatic disease.
Do not use in cases of hypersensitivity to the active substance or any of the
excipients.
Do not use in the case of cardiogenic shock and severe aortic stenosis.
AN: 00187/2025 and 00188/2025Page 2 of 7

Cats
Common
(1 to 10 animals / 100 animals
treated):
Digestive tract disorder (e.g. vomiting, diarrhoea)
a
Lethargy, Weight loss, Decreased appetite
a
Hypokalaemia
Uncommon
(1 to 10 animals / 1,000
animals
treated):
Hypotension
a
Mild and transient.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

In cats situational hypertension (also called white coat hypertension) occurs as a
consequence of the in-clinic measurement process in an otherwise normotensive
animal. In case of high stress levels measurement of systolic blood pressure may
lead to incorrect diagnosis of hypertension. It is recommended that stable
hypertension is confirmed by multiple and repeated measurement of systolic blood
pressure on different days before commencing therapy.
In case of secondary hypertension it is important to establish primary cause and/or
co-morbidities of hypertension, such as hyperthyroidism, chronic kidney disease and
diabetes and to treat these conditions.
Continued administration of the veterinary medicinal product over an extended period
of time should be in accordance with an ongoing benefit/risk evaluation, performed
by the prescribing veterinarian that includes measurement of systolic blood pressure
routinely during treatment (e.g. every 2 to 3 months). If needed dosages may be
adjusted.

Special precautions for safe use in the target species:
Special caution is required in patients with hepatic disease as amlodipine is highly
metabolised by the liver. Consequently amlodipine half-life may be prolonged and a
lower dose may be required. As no studies have been conducted in animals with liver
disease, use of the veterinary medicinal product in these animals should be based on
a benefit-risk assessment by the attending veterinarian.
Older cats with severe hypertension and chronic kidney disease (CKD) may suffer
from hypokalaemia as a result of their underlying disease. Administration of
amlodipine may sometimes result in a decrease in serum potassium and chloride
levels and could thus lead to exacerbation of hypokalaemia already present.
Monitoring of those concentrations is recommended before and during treatment.
No animals with severe unstable CKD were included in the clinical trials. Use of the
veterinary medicinal product in these animals should be based on a benefit-risk
assessment by the attending veterinarian.
Because amlodipine may have slight negative inotropic effects, the use of the
veterinary medicinal product in cardiac patients should be based on a benefit risk
assessment by the veterinarian. Safety has not been tested in cats with known heart
disease.
Animals weighing less than 2.5 kg were not included in the clinical trials. Animals
weighing between 2 and 2.5 kg should be treated with caution and based on a
benefit risk assessment by the responsible veterinarian.
Doses above 0.47 mg/kg bodyweight have not been examined in clinical trials with
the veterinary medicinal product and should only be administered with caution and
based on a benefit risk assessment by the attending veterinarian.
The tablets are flavoured. To avoid accidental ingestion, store tablets out of reach of
animals.
AN: 00187/2025 and 00188/2025Page 3 of 7
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
This veterinary medicinal product may cause hypersensitivity reactions. People with
known hypersensitivity to amlodipine should avoid contact with the veterinary
medicinal product. Wash hands after use.
Accidental ingestion by children, may cause a decrease in blood pressure. Unused
tablet parts should be placed back into the blister and carton and carefully kept away
from children. In case of accidental ingestion by a child seek medical advice
immediately and show the package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.

Concomitant use of diuretics, beta-blockers, other calcium channel blockers,
inhibitors of the renin angiotensin aldosterone system, other vasodilators, alpha-2
agonists or other agents that may reduce blood pressure may cause hypotension.
Concomitant use of cyclosporin or CYP3A4 strong inhibitors (eg. ketoconazole,
itraconazole) may cause increased amlodipine levels.

Do not store above 25 °C.
Divided tablets should be stored in the open blister pack.
Keep the blister package in the outer carton in order to protect from light.

After two weeks of treatment, the clinical response should be re-evaluated. In case of
insufficient clinical response - decrease in SBP less than 15% and SBP still > 150
mm Hg - dose may be increased by 0.5 mg (½ tablet) per day,up to a maximum
dose of 0.5 mg/kg BW daily. See also section 3.5.
Response to dose adjustments should be re-evaluated after another two weeks.
In the event of clinically relevant adverse events decreasing the dose or termination
of treatment should be considered.
3.10 Symptoms of overdose (and where applicable, emergency procedures and
antidotes)
Reduced appetite and weight loss occurred at a dose of 1 mg/day (corresponding to
0.32 mg/kg).
Lethargy started to occur in some cats receiving 3 mg amlodipine/daily (0.63 -1.11
mg/kg/day).
An overall shift in electrolyte balance (lowered potassium and chloride
concentrations) was detected in all animals receiving 3-5 mg amlodipine/daily (0.49 -
1.56 mg/kg).
Conjunctivitis and watery discharge from the eyes was noted in the highest dosed
animals, i.e. 1.02 - 1.47 mg/kg; however it is unclear if this is treatment related.
Reversable gingival hyperplasia has been described in literature after treatment with
2.5 mg of amlodipine per day for more than 300 days.
AN: 00187/2025 and 00188/2025Page 5 of 7
3.11 Special restrictions for use and special conditions for use, including
restrictions on the use of antimicrobial and antiparasitic veterinary
medicinal products in order to limit the risk of development of resistance
Not applicable.
3.12 Withdrawal periods
Not applicable.
4.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.